FDA Advisors Support New Alzheimer’s Drug
TUESDAY, June 11, 2024 (HealthDay News) — A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and bleeding. Eli Lilly’s donanemab did slow declines in thinking skills inContinue Reading